Galux, a South Korean biotech specializing in AI-driven protein therapeutics discovery, has entered into a research agreement with Boehringer Ingelheim to explore the application of artificial intelligence (AI) in precision protein design. This collaboration aims to evaluate how AI can be utilized to create purpose-specific protein molecules that address specific scientific and translational needs, particularly where traditional methods fall short.
According to Chaok Seok, CEO of Galux, this partnership is a significant step towards demonstrating that AI can transcend mere predictive capabilities to enable purposeful molecular design. The focus will be on developing proteins that align with clearly defined research and therapeutic objectives, thereby tackling challenges that demand tailored molecular solutions.
Earlier this year, Galux achieved a major milestone in de novo antibody design, successfully identifying novel antibodies with high binding affinity and specificity across various therapeutic targets. The initial phase of the collaboration will concentrate on validating the feasibility of AI-driven protein design, paving the way for expanded research initiatives between the two organizations. Seok emphasized that the future of therapeutics hinges on precise design, merging AI’s capabilities with biomedical science to unlock new therapeutic avenues.
Start your 7-day trial and see what the database can do →
